Hong YG - Search Results

1

A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.

Li N, Wu T, Hong YG, Guo YZ, Cheng YF, Ma YJ, Bie LY, Cui DH, Gao XH, Tan BX, Li BS, Luo SX, Wang JS. Li N, et al. Among authors: hong yg. BMC Med. 2022 Dec 8;20(1):472. doi: 10.1186/s12916-022-02649-x. BMC Med. 2022. PMID: 36482345 Free PMC article. Clinical Trial.

2

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.

Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, Luo Z, Xia J, Zhou Y, Xu M, Liu E, Jiang G, Li S, Zhao F, Ma C, Ma C, Hou Z, Li J, Wang J, Wang F. Meng X, et al. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):245-253. doi: 10.1016/S2468-1253(21)00378-2. Epub 2022 Jan 6. Lancet Gastroenterol Hepatol. 2022. PMID: 34998471 Clinical Trial.

3

Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study.

Meng X, Wang J, Xia J, Wu T, Luo Z, Hong Y, Lu P, Guo Y, Ji Y, Zhang M, Yang L, Cheng P, Liang W, Shan Z, Zhou Y, Wang M, Lu T, Song M, Zong H, Song L, Wang W, Guan L, Li Y, Xing J, Xing S, Wu H, Chu J, Luo X, Lu Y, Xin D, Li A, Jiang B, Li S, Jiang G, Fan Q, Zhao F, Zheng R, Zhu W, Hou Z, Jia Y, Wang F. Meng X, et al. Eur J Cancer. 2024 Nov;212:114328. doi: 10.1016/j.ejca.2024.114328. Epub 2024 Sep 12. Eur J Cancer. 2024. PMID: 39307038 Clinical Trial.

4

First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study.

Li N, Xia J, Gao X, Zhou J, Hong Y, Cui D, Zhao X, Wu T, Guo Y, Wang J, Luo S. Li N, et al. Signal Transduct Target Ther. 2024 Nov 8;9(1):303. doi: 10.1038/s41392-024-02008-7. Signal Transduct Target Ther. 2024. PMID: 39511164 Free PMC article. Clinical Trial.

5

Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study.

Hong Y, Liu J, Lu P, Chang Z, Zhang G, Ma X, Liang W, Tian Y, Xia J, Cao H, Huang J. Hong Y, et al. Oncologist. 2024 Sep 20:oyae245. doi: 10.1093/oncolo/oyae245. Online ahead of print. Oncologist. 2024. PMID: 39303674 Free article.

6

Transparent Rule Enablement Based on Commonization Approach in Heterogeneous IoT Edge Networks.

Jin W, Hong YG, Song J, Kim J, Kim D. Jin W, et al. Among authors: hong yg. Sensors (Basel). 2023 Oct 6;23(19):8282. doi: 10.3390/s23198282. Sensors (Basel). 2023. PMID: 37837112 Free PMC article.

7

The transcription factor NAC102 confers cadmium tolerance by regulating WAKL11 expression and cell wall pectin metabolism in Arabidopsis.

Han GH, Huang RN, Hong LH, Xu JX, Hong YG, Wu YH, Chen WW. Han GH, et al. Among authors: hong yg. J Integr Plant Biol. 2023 Oct;65(10):2262-2278. doi: 10.1111/jipb.13557. Epub 2023 Sep 13. J Integr Plant Biol. 2023. PMID: 37565550

8

Transplantation of adipose tissue-derived microvascular fragments promotes therapy of critical limb ischemia.

Park GT, Lim JK, Choi EB, Lim MJ, Yun BY, Kim DK, Yoon JW, Hong YG, Chang JH, Bae SH, Ahn JY, Kim JH. Park GT, et al. Among authors: hong yg. Biomater Res. 2023 Jul 16;27(1):70. doi: 10.1186/s40824-023-00395-6. Biomater Res. 2023. PMID: 37455318 Free PMC article.

9

Retraction Note: Downregulation of miR-196-5p induced by hypoxia drives tumorigenesis and metastasis in hepatocellular carcinoma.

Zheng H, Bi FR, Yang Y, Hong YG, Ni JS, Ma L, Liu MH, Hao LQ, Zhou WP, Song LH, Yan HL. Zheng H, et al. Among authors: hong yg. Discov Oncol. 2023 Apr 24;14(1):48. doi: 10.1007/s12672-023-00659-6. Discov Oncol. 2023. PMID: 37093499 Free PMC article. No abstract available.

10

Retraction Note: LncRNA LBX2-AS1 promotes colorectal cancer progression and 5-fluorouracil resistance.

Ma YN, Hong YG, Yu GY, Jiang SY, Zhao BL, Guo A, Wang Y, Cui XM, Hao LQ, Zheng H. Ma YN, et al. Among authors: hong yg. Cancer Cell Int. 2023 Feb 23;23(1):32. doi: 10.1186/s12935-023-02881-2. Cancer Cell Int. 2023. PMID: 36823633 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100 results

Search Page

Filters